文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

体外膜氧合治疗心源性休克:死亡率与并发症的荟萃分析

Extracorporeal membrane oxygenation for cardiogenic shock: a meta-analysis of mortality and complications.
PubMed 文献 · Ann Intensive Care · 2022-10-05
一句话结论va-ECMO治疗心源性休克院内死亡合并估计62%,肾衰竭51%、需肾脏替代治疗44%、出血49%,作者认为需随机试验验证其有效性。

该系统评价与荟萃分析按PRISMA指南检索Medline(PubMed)和Scopus(Elsevier)数据库至2022年5月,纳入32项研究共12756例接受va-ECMO支持的心源性休克患者。1994年至2019年间,院内死亡合并估计为62%(8493/12756),超过三分之一患者在ECMO支持期间死亡;最常见并发症为肾衰竭51%(693/1351)、需肾脏替代治疗44%(4879/11186)和出血49%(1971/4523)。单变量荟萃回归显示年龄超过60岁、ECMO持续时间较短和存在感染与院内死亡相关,而报告穿刺部位出血发生率较高的研究意外地与院内死亡降低相关。作者认为va-ECMO是有创生命支持且并发症风险高,需制定方案和技术以减少不良事件,并需随机试验证明其在心源性休克中的有效性。

要点

  • 32项研究共12756例心源性休克患者接受va-ECMO,院内死亡合并估计62%(8493/12756),超过三分之一在ECMO支持期间死亡。
  • 最常见并发症:肾衰竭51%(693/1351)、需肾脏替代治疗44%(4879/11186)、出血49%(1971/4523),可能造成永久损伤或死亡。
  • 单变量荟萃回归中,年龄超过60岁、ECMO持续时间较短和存在感染与院内死亡相关。
  • 报告穿刺部位出血发生率较高的研究意外地与院内死亡降低相关。
  • 作者认为需制定方案和技术以减少不良事件,并需随机试验证明va-ECMO在心源性休克中的有效性。

适用人群与场景

  • 接受va-ECMO支持的危重心源性休克患者,ECMO作为临时支持为恢复、永久辅助或移植争取时间。
  • 纳入文献发表至2022年5月,研究覆盖1994年至2019年。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,按PRISMA指南检索Medline(PubMed)和Scopus(Elsevier)数据库至2022年5月,采用按研究大小的加权随机效应模型进行合并估计。
  • 共纳入32项研究、12756例患者;1994年至2019年间院内死亡合并估计62%(8493/12756),超过三分之一患者在ECMO支持期间死亡。
  • 最常见并发症为肾衰竭51%(693/1351)、需肾脏替代治疗44%(4879/11186)、出血49%(1971/4523)。
  • 单变量荟萃回归分析:年龄超过60岁、ECMO持续时间较短、存在感染与院内死亡相关;报告穿刺部位出血发生率较高的研究意外地与院内死亡降低相关。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析(32项研究,12756例患者)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为va-ECMO是有创生命支持且并发症风险高,需制定方案和技术以减少不良事件发生率。
  • 作者认为需要随机试验证明va-ECMO在心源性休克中的有效性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Venoarterial extracorporeal membrane oxygenation (va-ECMO) is an advanced life support for critically ill patients with refractory cardiogenic shock. This temporary support bridges time for recovery, permanent assist, or transplantation in patients with high risk of mortality. However, the benefit of this modality is still subject of discussion and despite the continuous development of critical care medicine, severe cardiogenic shock remains associated with high mortality. Therefore, this work aims to analyze the current literature regarding in-hospital mortality and complication rates of va-ECMO in patients with cardiogenic shock.

METHODS: We conducted a systematic review and meta-analysis of the most recent literature to analyze the outcomes of va-ECMO support. Using the PRISMA guidelines, Medline (PubMed) and Scopus (Elsevier) databases were systematically searched up to May 2022. Meta-analytic pooled estimation of publications variables was performed using a weighted random effects model for study size.

RESULTS: Thirty-two studies comprising 12756 patients were included in the final analysis. Between 1994 and 2019, 62% (pooled estimate, 8493/12756) of patients died in the hospital. More than one-third of patients died during ECMO support. The most frequent complications were renal failure (51%, 693/1351) with the need for renal replacement therapy (44%, 4879/11186) and bleeding (49%, 1971/4523), bearing the potential for permanent injury or death. Univariate meta-regression analyses identified age over 60 years, shorter ECMO duration and presence of infection as variables associated with in-hospital mortality, while the studies reporting a higher incidence of cannulation site bleeding were unexpectedly associated with a reduced in-hospital mortality.

CONCLUSIONS: Extracorporeal membrane oxygenation is an invasive life support with a high risk of complications. We identified a pooled in-hospital mortality of 62% with patient age, infection and ECMO support duration being associated with a higher mortality. Protocols and techniques must be developed to reduce the rate of adverse events. Finally, randomized trials are necessary to demonstrate the effectiveness of va-ECMO in cardiogenic shock.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Rajsic S, Treml B, Jadzic D, et al. Extracorporeal membrane oxygenation for cardiogenic shock: a meta-analysis of mortality and complications. Ann Intensive Care. 2022. PMID: 36195759. doi:10.1186/s13613-022-01067-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。